Cellid Co. Ltd
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) an… Read more
Cellid Co. Ltd - Asset Resilience Ratio
Cellid Co. Ltd (299660) has an Asset Resilience Ratio of 11.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Cellid Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cellid Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩13.12 Billion | 11.66% |
| Total Liquid Assets | ₩13.12 Billion | 11.66% |
Asset Resilience Insights
- Moderate Liquidity: Cellid Co. Ltd has 11.66% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Cellid Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Cellid Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Cellid Co. Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Cellid Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.91% | ₩9.06 Billion | ₩76.09 Billion | -11.59pp |
| 2023-12-31 | 23.50% | ₩15.02 Billion | ₩63.92 Billion | -17.24pp |
| 2022-12-31 | 40.74% | ₩18.68 Billion | ₩45.86 Billion | +6.52pp |
| 2021-12-31 | 34.23% | ₩19.94 Billion | ₩58.26 Billion | +9.79pp |
| 2020-12-31 | 24.43% | ₩12.07 Billion | ₩49.40 Billion | +21.38pp |
| 2019-12-31 | 3.05% | ₩1.60 Billion | ₩52.52 Billion | -52.42pp |
| 2018-12-31 | 55.47% | ₩7.89 Billion | ₩14.22 Billion | -35.40pp |
| 2017-12-31 | 90.86% | ₩4.51 Billion | ₩4.96 Billion | +4.43pp |
| 2016-12-31 | 86.44% | ₩3.29 Billion | ₩3.81 Billion | -- |